Imagion Biosystems is pleased to announce that it has successfully applied for an Advance/Overseas Finding in relation to its research and development activities for a new superparamagnetic based imaging technology for detection of HER2 breast cancers.
View the announcement.
Imagion Initiates Manufacturing of MagSense® Drug for Phase 2 Clinical Study on HER2+ Breast Cancer
February 19, 2025
MELBOURNE – Imagion Biosystems (Company) (ASX : IBX), a company dedicated to improving healthcare outcomes through the early detection of cancer, is pleased to announce